Literature DB >> 15541065

The current status of psychological treatments in bipolar disorders: a systematic review of relapse prevention.

Jan Scott1, Maria Jose Gutierrez.   

Abstract

OBJECTIVE: This paper reviews published randomized-controlled treatment trials of psychological therapies added to standard psychiatric treatment versus medication and standard psychiatric treatment alone to explore whether adjunctive psychotherapy reduces relapse rates in individuals with bipolar disorders (BDs).
METHOD: Relapse rates were calculated for individual trials that met inclusion criteria and then pooled odds ratios were calculated using meta-analytic techniques.
RESULTS: The majority of studies quoted demonstrate that individuals receiving psychological treatments had significantly fewer relapses. The length of therapy required was between 10 and 20 h over 6-9 months and the models of effective therapies had many shared characteristics in terms of style and content.
CONCLUSIONS: Adjunctive psychological treatments for individuals with BDs are acceptable and feasible and reduce relapse risk. There are relatively few differences in the benefits that accrue from the different therapy models. It is now important to explore whether they have added value in terms of additional health gains and social functioning compared with standard treatment approaches. Blackwell Munksgaard, 2004

Entities:  

Mesh:

Year:  2004        PMID: 15541065     DOI: 10.1111/j.1399-5618.2004.00153.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  10 in total

1.  More than medication-achieving psychotherapy goals in patients with bipolar disorder in challenging settings.

Authors:  Brenda J B Roman; Paulette Marie Gillig
Journal:  Psychiatry (Edgmont)       Date:  2006-03

2.  Common and specific elements of psychosocial treatments for bipolar disorder: a survey of clinicians participating in randomized trials.

Authors:  David J Miklowitz; Guy M Goodwin; Mark S Bauer; John R Geddes
Journal:  J Psychiatr Pract       Date:  2008-03       Impact factor: 1.325

Review 3.  The clinical significance of creativity in bipolar disorder.

Authors:  Greg Murray; Sheri L Johnson
Journal:  Clin Psychol Rev       Date:  2010-05-27

4.  Tendencies Toward Mania and Tendencies Toward Depression Have Distinct Motivational, Affective, and Cognitive Correlates.

Authors:  Charles S Carver; Sheri L Johnson
Journal:  Cognit Ther Res       Date:  2009-12

5.  Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program.

Authors:  David J Miklowitz; Michael W Otto; Ellen Frank; Noreen A Reilly-Harrington; Stephen R Wisniewski; Jane N Kogan; Andrew A Nierenberg; Joseph R Calabrese; Lauren B Marangell; Laszlo Gyulai; Mako Araga; Jodi M Gonzalez; Edwin R Shirley; Michael E Thase; Gary S Sachs
Journal:  Arch Gen Psychiatry       Date:  2007-04

Review 6.  Long-term prophylaxis in bipolar disorder.

Authors:  Matthew J Taylor; Guy M Goodwin
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 7.  Evidence-based research on the efficacy of psychologic interventions in bipolar disorders: a critical review.

Authors:  Eduard Vieta; Isabella Pacchiarotti; Jan Scott; Jose Sánchez-Moreno; Sylvia Di Marzo; Francesc Colom
Journal:  Curr Psychiatry Rep       Date:  2005-12       Impact factor: 5.285

Review 8.  An update on the role of psychotherapy in the management of bipolar disorder.

Authors:  David J Miklowitz
Journal:  Curr Psychiatry Rep       Date:  2006-12       Impact factor: 5.285

9.  Does a home treatment acute relapse prevention strategy reduce admissions for people with mania in bipolar affective disorder?

Authors:  Claudia Murton; Michael Cooper; Stephen Dinniss; Shon Roberts; Nicola Booth; Paul Newell
Journal:  Psychiatr Bull (2014)       Date:  2014-12

Review 10.  Management of bipolar disorders in women by nonpharmacological methods.

Authors:  Sujit Kumar Naik
Journal:  Indian J Psychiatry       Date:  2015-07       Impact factor: 1.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.